Goodsurance
ES

Drug prices & Part D

Fifteen Medicare Part D Drugs Will Have Federally Negotiated Prices in 2027, Including Ozempic

With open enrollment opening October 15, every Part D and Medicare Advantage drug plan will be required to cover all 15 negotiated medicines at or below their maximum fair prices starting January 1.

By the Goodsurance editorial teamOctober 6, 2026

The Medicare drug price negotiation program's second set of lower prices takes effect January 1, 2027, covering 15 widely used Part D medications including the semaglutide group, which includes Ozempic, Rybelsus, and Wegovy.

Under the Inflation Reduction Act, the Centers for Medicare and Medicaid Services set maximum fair prices with manufacturers after the 15 drugs were selected for the second negotiation cycle. The selected drugs treat Type 2 diabetes, asthma, chronic obstructive pulmonary disease, cancer, and other conditions. The maximum fair price for semaglutide products, including Ozempic and Wegovy, is 274 dollars for a 30-day supply, compared with a list price of 959 dollars before negotiation. CMS estimates total savings of about 12 billion dollars relative to 2024 net prices across all 15 drugs, and roughly 685 million dollars in out-of-pocket savings for Medicare beneficiaries.

Ozempic is one of 15 Medicare Part D drugs with a federally negotiated price starting January 1. Open enrollment opens October 15.

All stand-alone Part D drug plans and Medicare Advantage plans with drug coverage are required to include these 15 medicines on their formularies at prices at or below the maximum fair prices. However, what a beneficiary pays at the pharmacy depends on the plan's tier placement, deductibles, and cost-sharing rules, which differ from plan to plan. Medicare Part D covers semaglutide products only when prescribed for Type 2 diabetes, not for weight loss.

The annual enrollment period, which opens October 15 and closes December 7, is when people with Medicare can join, switch, or drop a Part D or Medicare Advantage plan for 2027. The Medicare Plan Finder at Medicare.gov allows beneficiaries to enter their specific prescriptions and compare estimated costs across available plans in their area.

In plain words

Starting January 1, 2027, all Medicare drug plans must cover 15 medicines at lower prices set by the federal government. One of them is Ozempic, which treats Type 2 diabetes. The new price is 274 dollars for a 30-day supply. Before the government stepped in, the list price was 959 dollars. Every Part D plan must offer these drugs. But how much you pay at the pharmacy still depends on your plan's own rules.

Open enrollment starts October 15 and ends December 7. That is the time each year when you can switch or join a Medicare drug plan. You can compare plans at Medicare.gov. Enter your medicines to see which plan costs you less.

Source: CMS
Read at the source →

More news

Other stories on what is moving in Medicare.

Drug prices & Part D

Medicare Part D Rarely Covers the OTC Naloxone Nasal Spray. Medicaid Usually Does.

A new Government Accountability Office report finds that most Part D plans stopped covering the over-the-counter naloxone nasal spray after it no longer required a prescription, while Medicaid covers the same product at little or no cost to enrollees.

November 16, 2026

Drug prices & Part D

Biotech Industry Group Files Second Lawsuit to Block Medicare's GLOBE Drug Pricing Model

BIO and two California biotech groups sued CMS on November 6, arguing the program exceeds legal authority. A first challenge from PhRMA filed in October remains pending.

November 12, 2026

Drug prices & Part D

KFF: Medicare's 340B Drug Payment Cut Reduces Revenue for Safety-Net Hospitals While Raising It for For-Profit Ones

Now that the 2027 outpatient rule is final, a KFF analysis finds the 340B reimbursement cut falls hardest on hospitals that serve low-income patients, while for-profit hospitals see a net gain.

November 11, 2026

Drug prices & Part D

Medicare Drug Price Negotiation Rules Are Now Permanent, Federal Register Shows

The CMS-4215-F final rule, published today, converts the negotiation program from administrative guidance into binding federal regulation for every drug-price cycle starting in 2029, and requires Part D plans to cover negotiated-price drugs on their formularies.

November 9, 2026

Drug prices & Part D

Third Medicare Drug Negotiation Cycle Closes, Including Part B Doctor-Office Drugs for the First Time

The formal negotiation period for 15 drugs ended November 1; CMS must publish any agreed-upon maximum fair prices by November 30, including the first-ever negotiated prices for drugs given in doctors' offices.

November 1, 2026

Drug prices & Part D

Average Medicare Part D Stand-Alone Premium Projected to Rise 50 Percent for 2027, KFF Finds

A KFF analysis published today finds the average monthly premium for stand-alone Part D drug plans is on track to climb from 34 dollars to 51 dollars for 2027, with deductibles also rising sharply, for enrollees who do not switch plans before December 7.

October 30, 2026